Q32 Bio (QTTB) EBIT (2017 - 2026)

Q32 Bio's EBIT history runs 10 years deep, the most recent figure standing at -$7.7 million for Q1 2026.

• In Q1 2026, EBIT rose 36.85% year-over-year to -$7.7 million; the TTM figure through Mar 2026 stood at $21.4 million (up 133.72% YoY), while the FY2025 annual figure was $16.9 million, up 125.57% from the prior year.
• EBIT was -$7.7 million for Q1 2026 at Q32 Bio, down from $45.9 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $97.9 million in Q4 2022 to a low of -$37.6 million in Q1 2022.
• Historically, EBIT has averaged -$6.2 million across 5 years, with a median of -$12.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: EBIT tumbled 3285.96% in 2022, then jumped 415.84% in 2025.
• A 5-year view of EBIT shows it stood at $97.9 million in 2022, then sank by 126.37% to -$25.8 million in 2023, then surged by 43.72% to -$14.5 million in 2024, then surged by 415.84% to $45.9 million in 2025, then sank by 116.83% to -$7.7 million in 2026.
• The last three EBIT figures came in at -$7.7 million (Q1 2026), $45.9 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.